palbociclib,fulvestrant
pfizer
['kudos', 'palbociclib', 'palbo']
kudos to &amp; dutch colleagues for funding/delivering sonia trial #asco23 has demonstrated that the use of first-line cdk4/6i vs second-line cdk4/6i doesn t increase pfs2(31 vs 28.8 mths) or os (45.9 vs 53.7 mths). 91% received palbociclib as cdk4/6i. 
Professor of Translational Oncology and Consultant Medical Oncologist